BidaskClub upgraded shares of Cellular Biomedicine Group (NASDAQ:CBMG) from a sell rating to a hold rating in a research note published on Tuesday.
Several other research analysts have also weighed in on CBMG. Zacks Investment Research upgraded shares of Cellular Biomedicine Group from a sell rating to a hold rating in a research note on Monday, July 23rd. B. Riley boosted their price objective on shares of Cellular Biomedicine Group from $32.00 to $38.00 and gave the stock a buy rating in a research note on Wednesday, October 3rd. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company has a consensus rating of Hold and a consensus price target of $28.50.
Cellular Biomedicine Group stock opened at $14.32 on Tuesday. The stock has a market cap of $263.53 million, a PE ratio of -8.04 and a beta of 3.45. Cellular Biomedicine Group has a fifty-two week low of $9.80 and a fifty-two week high of $25.00.
Cellular Biomedicine Group (NASDAQ:CBMG) last released its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.04). The firm had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.05 million. Cellular Biomedicine Group had a negative return on equity of 47.52% and a negative net margin of 10,133.88%. Research analysts predict that Cellular Biomedicine Group will post -1.74 earnings per share for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in CBMG. Rhumbline Advisers acquired a new position in shares of Cellular Biomedicine Group during the 2nd quarter worth about $208,000. Wells Fargo & Company MN boosted its holdings in shares of Cellular Biomedicine Group by 29.7% during the 3rd quarter. Wells Fargo & Company MN now owns 17,946 shares of the biotechnology company’s stock worth $326,000 after buying an additional 4,114 shares during the period. Schwab Charles Investment Management Inc. bought a new stake in shares of Cellular Biomedicine Group during the 2nd quarter worth about $423,000. Northern Trust Corp boosted its holdings in shares of Cellular Biomedicine Group by 22.9% during the 1st quarter. Northern Trust Corp now owns 37,980 shares of the biotechnology company’s stock worth $667,000 after buying an additional 7,076 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Cellular Biomedicine Group by 208.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 34,579 shares of the biotechnology company’s stock worth $676,000 after buying an additional 23,354 shares during the period. Institutional investors own 7.61% of the company’s stock.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer, orthopedic, and metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; tumor cell specific dendritic cell therapy; and Re-Join therapy and AlloJoin therapy for the treatment of knee osteoarthritis.
Featured Article: What is the Ex-Dividend Date in Investing?
Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.